Vincristine Sulfate | Drug Information, Uses, Side Effects

Go to content

Main menu:

Vincasar PFS | Medidex

Interesting
Vincristine Sulfate | Drug Information, Uses, Side Effects , Vincasar PFS | Medidex, Vincristine - FDA prescribing information, side effects , Vincristine Side Effects - Leukemia Home Page, DailyMed - VINCASAR PFS- vincristine sulfate injection , FDA Drug Shortages, Vincristine Sulfate | All | Licensing, EU CTD Dossiers , Vincristine sulfate | C46H58N4O14S - PubChem.
GeneralAcute uric acid nephropathy, which may occur after the administration of oncolytic agents, has also been reported with vincristine sulfate. In the presence of leukopenia or a complicating infection, administration of the next dose of VINCASAR PFS warrants careful consideration.If central nervous system leukemia is diagnosed, additional agents may be required, because vincristine does not appear to cross the blood-brain barrier in adequate amounts.Particular attention should be given to dosage and neurologic side effects if VINCASAR PFS is administered to patients with preexisting neuromuscular disease and when other drugs with neurotoxic potential are also being used.Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids. These reactions have been encountered most frequently when the vinca alkaloid was used in combination with mitomycin-C and may require aggressive treatment, particularly when there is preexisting pulmonary dysfunction. The onset of these reactions may occur minutes to several hours after the vinca alkaloid is injected and may occur up to 2 weeks following the dose of mitomycin. Progressive dyspnea requiring chronic therapy may occur. VINCASAR PFS should not be readministered.Care must be taken to avoid contamination of the eye with concentration of VINCASAR PFS used clinically. If accidental contamination occurs, severe irritation (or, if the drug was delivered under pressure, even corneal ulceration) may result. The eye should be washed immediately and thoroughly.Laboratory TestsBecause dose-limiting clinical toxicity is manifested as neurotoxicity, clinical evaluation (e.g., history, physical examination) is necessary to detect the need for dosage modification. Following administration of VINCASAR PFS, some individuals may have a fall in the white blood cell count or platelet count, particularly when previous therapy or the disease itself has reduced bone-marrow function. Therefore, a complete blood count should be done before administration of each dose. Acute elevation of serum uric acid may also occur during induction of remission in acute leukemia; thus, such levels should be determined frequently during the first 3 to 4 weeks of treatment or appropriate measures taken to prevent uric acid nephropathy. The laboratory performing these tests should be consulted for its range of normal values.Drug InteractionsThe simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity.  Dosage adjustment should be based on serial blood level monitoring. The contribution of vincristine sulfate to this interaction is not certain. The interaction may result from reduced absorption of phenytoin and an increase in the rate of its metabolism and elimination.Caution should be exercised in patients concurrently taking drugs known to inhibit drug metabolism by hepatic cytochrome P450 isoenzymes in the CYP 3A subfamily, or in patients with hepatic dysfunction. Concurrent administration of vincristine sulfate with itraconazole (a known inhibitor of the metabolic pathway) has been reported to cause an earlier onset and/or an increased severity of neuromuscular side effects (see ). This interaction is presumed to be related to inhibition of the metabolism of vincristine.Carcinogenesis, Mutagenesis, Impairment of FertilityNeither nor laboratory tests have conclusively demonstrated the mutagenicity of this product.  Fertility following treatment with vincristine sulfate alone for malignant disease has not been studied in humans. Clinical reports of both male and female patients who received multiple-agent chemotherapy that included vincristine sulfate indicate that azoospermia and amenorrhea can occur in postpubertal patients. Recovery occurred many months after completion of chemotherapy in some but not all patients. When the same treatment is administered to prepubertal patients, permanent azoospermia and amenorrhea are much less likely.  Patients who received chemotherapy with vincristine sulfate in combination with anti-cancer drugs known to be carcinogenic have developed second malignancies. The contributing role of vincristine sulfate in this development has not been determined. No evidence of carcinogenicity was found following intraperitoneal administration of vincristine sulfate in rats and mice, although this study was limited.  USAGE IN PREGNANCY ArrayArrayArrayArrayNursing MothersIt is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions due to vincristine sulfate in nursing infants, a decision should be made either to discontinue nursing or the drug, taking into account the importance of the drug to the mother.Pediatric UseSee section.. Vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, and Wilms' tumor..
Vincristine Sulfate, USP is a white to slightly yellow powder. It is soluble in methanol, freely soluble in water, but only slightly soluble in 95% ethanol. In 98% ethanol, vincristine sulfate, USP has an ultraviolet spectrum with maxima at 221 nm (∈ +47,100).. Vincristine Sulfate Injection, USP is the salt of an alkaloid obtained from a common flowering herb, the periwinkle plant (Vinca rosea Linn). Originally known as leurocristine, it has also been referred to as LCR and VCR.. Just like any medicine, vincristine sulfate (Vincasar PFS ®) can cause side effects. In fact, most people will experience some type of reaction to this drug, and some side effects can be quite significant. Talk to your healthcare provider about ways to prevent or lessen reactions to this medicine.. VINCASAR PFS (vincristine sulfate injection USP) is vincaleukoblastine, 22-oxo-, sulfate (1:1) (salt). It is the salt of an alkaloid obtained from a common flowering herb, the periwinkle plant ( Vinca rosea Linn).. FDA Drug Shortages. List of All Manufacturers & Suppliers of Vincristine Sulfate Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com.
 
Copyright 2019. All rights reserved.
Back to content | Back to main menu